127 related articles for article (PubMed ID: 26776155)
1. Integrative bioinformatics and proteomics-based discovery of an eEF2K inhibitor (cefatrizine) with ER stress modulation in breast cancer cells.
Yao Z; Li J; Liu Z; Zheng L; Fan N; Zhang Y; Jia N; Lv J; Liu N; Zhu X; Du J; Lv C; Xie F; Liu Y; Wang X; Fei Z; Gao C
Mol Biosyst; 2016 Mar; 12(3):729-36. PubMed ID: 26776155
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer.
Guo Y; Zhao Y; Wang G; Chen Y; Jiang Y; Ouyang L; Liu B
Eur J Med Chem; 2018 Jan; 143():402-418. PubMed ID: 29202403
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G
Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948
[TBL] [Abstract][Full Text] [Related]
4. Integrated regulation of autophagy and apoptosis by EEF2K controls cellular fate and modulates the efficacy of curcumin and velcade against tumor cells.
Cheng Y; Ren X; Zhang Y; Shan Y; Huber-Keener KJ; Zhang L; Kimball SR; Harvey H; Jefferson LS; Yang JM
Autophagy; 2013 Feb; 9(2):208-19. PubMed ID: 23182879
[TBL] [Abstract][Full Text] [Related]
5. Eukaryotic elongation factor-2 kinase (eEF2K): a potential therapeutic target in cancer.
Fu LL; Xie T; Zhang SY; Liu B
Apoptosis; 2014 Oct; 19(10):1527-31. PubMed ID: 25023961
[TBL] [Abstract][Full Text] [Related]
6. Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.
Karakas D; Ozpolat B
J Mol Med (Berl); 2020 Jun; 98(6):775-787. PubMed ID: 32377852
[TBL] [Abstract][Full Text] [Related]
7. Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases.
Liu R; Proud CG
Acta Pharmacol Sin; 2016 Mar; 37(3):285-94. PubMed ID: 26806303
[TBL] [Abstract][Full Text] [Related]
8. Computational design, chemical synthesis, and biological evaluation of a novel ERK inhibitor (BL-EI001) with apoptosis-inducing mechanisms in breast cancer.
Liu B; Fu L; Zhang C; Zhang L; Zhang Y; Ouyang L; He G; Huang J
Oncotarget; 2015 Mar; 6(9):6762-75. PubMed ID: 25742792
[TBL] [Abstract][Full Text] [Related]
9. Regulated stability of eukaryotic elongation factor 2 kinase requires intrinsic but not ongoing activity.
Wang X; Xie J; da Mota SR; Moore CE; Proud CG
Biochem J; 2015 Apr; 467(2):321-31. PubMed ID: 25670349
[TBL] [Abstract][Full Text] [Related]
10. SIRT1 Protects the Heart from ER Stress-Induced Injury by Promoting eEF2K/eEF2-Dependent Autophagy.
Pires Da Silva J; Monceaux K; Guilbert A; Gressette M; Piquereau J; Novotova M; Ventura-Clapier R; Garnier A; Lemaire C
Cells; 2020 Feb; 9(2):. PubMed ID: 32059483
[TBL] [Abstract][Full Text] [Related]
11. Eukaryotic elongation factor 2 kinase controls proliferation and migration of vascular smooth muscle cells.
Usui T; Nijima R; Sakatsume T; Otani K; Kameshima S; Okada M; Yamawaki H
Acta Physiol (Oxf); 2015 Feb; 213(2):472-80. PubMed ID: 25069823
[TBL] [Abstract][Full Text] [Related]
12. Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies.
Onder FC; Durdagi S; Kahraman N; Uslu TN; Kandemir H; Atici EB; Ozpolat B; Ay M
Bioorg Chem; 2021 Nov; 116():105296. PubMed ID: 34488125
[TBL] [Abstract][Full Text] [Related]
13. Designing an eEF2K-Targeting PROTAC small molecule that induces apoptosis in MDA-MB-231 cells.
Liu Y; Zhen Y; Wang G; Yang G; Fu L; Liu B; Ouyang L
Eur J Med Chem; 2020 Oct; 204():112505. PubMed ID: 32717479
[TBL] [Abstract][Full Text] [Related]
14. [Eukaryotic elongation factor 2 kinase and cancer].
Wang GZ; Qi X; Li J
Yao Xue Xue Bao; 2015 Jul; 50(7):808-13. PubMed ID: 26552140
[TBL] [Abstract][Full Text] [Related]
15. Eukaryotic elongation factor 2 kinase upregulates the expression of proteins implicated in cell migration and cancer cell metastasis.
Xie J; Shen K; Lenchine RV; Gethings LA; Trim PJ; Snel MF; Zhou Y; Kenney JW; Kamei M; Kochetkova M; Wang X; Proud CG
Int J Cancer; 2018 May; 142(9):1865-1877. PubMed ID: 29235102
[TBL] [Abstract][Full Text] [Related]
16. Fluoxetine induces autophagic cell death via eEF2K-AMPK-mTOR-ULK complex axis in triple negative breast cancer.
Sun D; Zhu L; Zhao Y; Jiang Y; Chen L; Yu Y; Ouyang L
Cell Prolif; 2018 Apr; 51(2):e12402. PubMed ID: 29094413
[TBL] [Abstract][Full Text] [Related]
17. Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy.
Zhang B; Zou J; Zhang Q; Wang Z; Wang N; He S; Zhao Y; Naman CB
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673713
[TBL] [Abstract][Full Text] [Related]
18. PPARγ-inactive Δ2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells.
Colin-Cassin C; Yao X; Cerella C; Chbicheb S; Kuntz S; Mazerbourg S; Boisbrun M; Chapleur Y; Diederich M; Flament S; Grillier-Vuissoz I
Mol Carcinog; 2015 May; 54(5):393-404. PubMed ID: 24293218
[TBL] [Abstract][Full Text] [Related]
19. Novel triterpenoid AECHL-1 induces apoptosis in breast cancer cells by perturbing the mitochondria-endoplasmic reticulum interactions and targeting diverse apoptotic pathways.
Sawant MA; Dasgupta A; Lavhale MS; Sitasawad SL
Biochim Biophys Acta; 2016 Jun; 1860(6):1056-70. PubMed ID: 26851676
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting Eukaryotic Elongation Factor 2 Kinase: An Update on Pharmacological Small-Molecule Compounds in Cancer.
Zhu S; Liao M; Tan H; Zhu L; Chen Y; He G; Liu B
J Med Chem; 2021 Jul; 64(13):8870-8883. PubMed ID: 34162208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
